Research ArticleArticle
Requirement of Apoptotic Protease-Activating Factor-1 for Bortezomib-Induced Apoptosis but Not for Fas-Mediated Apoptosis in Human Leukemic Cells
Astrid Ottosson-Wadlund, Rebecca Ceder, Giulio Preta, Katja Pokrovskaja, Roland C. Grafström, Mats Heyman, Stefan Söderhäll, Dan Grandér, Ingrid Hedenfalk, John D. Robertson and Bengt Fadeel
Molecular Pharmacology January 2013, 83 (1) 245-255; DOI: https://doi.org/10.1124/mol.112.080788
Astrid Ottosson-Wadlund
Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden (A.O.-W., R.C., G.P., R.C.G., B.F.); VTT Technical Research Centre of Finland, Medical Biotechnology, Turku, Finland (R.C.G.); Department of Oncology and Pathology, Cancer Centre Karolinska (K.P., M.H., S.S., D.G.) and Childhood Cancer Research Unit, Department of Women’s and Children’s Health (B.F.), Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden (I.H.); and Department of Pharmacology, Toxicology & Therapeutics, and the University of Kansas Cancer Center, University of Kansas Medical Center, Kansas City, Kansas (J.D.R.)
Rebecca Ceder
Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden (A.O.-W., R.C., G.P., R.C.G., B.F.); VTT Technical Research Centre of Finland, Medical Biotechnology, Turku, Finland (R.C.G.); Department of Oncology and Pathology, Cancer Centre Karolinska (K.P., M.H., S.S., D.G.) and Childhood Cancer Research Unit, Department of Women’s and Children’s Health (B.F.), Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden (I.H.); and Department of Pharmacology, Toxicology & Therapeutics, and the University of Kansas Cancer Center, University of Kansas Medical Center, Kansas City, Kansas (J.D.R.)
Giulio Preta
Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden (A.O.-W., R.C., G.P., R.C.G., B.F.); VTT Technical Research Centre of Finland, Medical Biotechnology, Turku, Finland (R.C.G.); Department of Oncology and Pathology, Cancer Centre Karolinska (K.P., M.H., S.S., D.G.) and Childhood Cancer Research Unit, Department of Women’s and Children’s Health (B.F.), Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden (I.H.); and Department of Pharmacology, Toxicology & Therapeutics, and the University of Kansas Cancer Center, University of Kansas Medical Center, Kansas City, Kansas (J.D.R.)
Katja Pokrovskaja
Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden (A.O.-W., R.C., G.P., R.C.G., B.F.); VTT Technical Research Centre of Finland, Medical Biotechnology, Turku, Finland (R.C.G.); Department of Oncology and Pathology, Cancer Centre Karolinska (K.P., M.H., S.S., D.G.) and Childhood Cancer Research Unit, Department of Women’s and Children’s Health (B.F.), Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden (I.H.); and Department of Pharmacology, Toxicology & Therapeutics, and the University of Kansas Cancer Center, University of Kansas Medical Center, Kansas City, Kansas (J.D.R.)
Roland C. Grafström
Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden (A.O.-W., R.C., G.P., R.C.G., B.F.); VTT Technical Research Centre of Finland, Medical Biotechnology, Turku, Finland (R.C.G.); Department of Oncology and Pathology, Cancer Centre Karolinska (K.P., M.H., S.S., D.G.) and Childhood Cancer Research Unit, Department of Women’s and Children’s Health (B.F.), Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden (I.H.); and Department of Pharmacology, Toxicology & Therapeutics, and the University of Kansas Cancer Center, University of Kansas Medical Center, Kansas City, Kansas (J.D.R.)
Mats Heyman
Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden (A.O.-W., R.C., G.P., R.C.G., B.F.); VTT Technical Research Centre of Finland, Medical Biotechnology, Turku, Finland (R.C.G.); Department of Oncology and Pathology, Cancer Centre Karolinska (K.P., M.H., S.S., D.G.) and Childhood Cancer Research Unit, Department of Women’s and Children’s Health (B.F.), Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden (I.H.); and Department of Pharmacology, Toxicology & Therapeutics, and the University of Kansas Cancer Center, University of Kansas Medical Center, Kansas City, Kansas (J.D.R.)
Stefan Söderhäll
Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden (A.O.-W., R.C., G.P., R.C.G., B.F.); VTT Technical Research Centre of Finland, Medical Biotechnology, Turku, Finland (R.C.G.); Department of Oncology and Pathology, Cancer Centre Karolinska (K.P., M.H., S.S., D.G.) and Childhood Cancer Research Unit, Department of Women’s and Children’s Health (B.F.), Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden (I.H.); and Department of Pharmacology, Toxicology & Therapeutics, and the University of Kansas Cancer Center, University of Kansas Medical Center, Kansas City, Kansas (J.D.R.)
Dan Grandér
Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden (A.O.-W., R.C., G.P., R.C.G., B.F.); VTT Technical Research Centre of Finland, Medical Biotechnology, Turku, Finland (R.C.G.); Department of Oncology and Pathology, Cancer Centre Karolinska (K.P., M.H., S.S., D.G.) and Childhood Cancer Research Unit, Department of Women’s and Children’s Health (B.F.), Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden (I.H.); and Department of Pharmacology, Toxicology & Therapeutics, and the University of Kansas Cancer Center, University of Kansas Medical Center, Kansas City, Kansas (J.D.R.)
Ingrid Hedenfalk
Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden (A.O.-W., R.C., G.P., R.C.G., B.F.); VTT Technical Research Centre of Finland, Medical Biotechnology, Turku, Finland (R.C.G.); Department of Oncology and Pathology, Cancer Centre Karolinska (K.P., M.H., S.S., D.G.) and Childhood Cancer Research Unit, Department of Women’s and Children’s Health (B.F.), Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden (I.H.); and Department of Pharmacology, Toxicology & Therapeutics, and the University of Kansas Cancer Center, University of Kansas Medical Center, Kansas City, Kansas (J.D.R.)
John D. Robertson
Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden (A.O.-W., R.C., G.P., R.C.G., B.F.); VTT Technical Research Centre of Finland, Medical Biotechnology, Turku, Finland (R.C.G.); Department of Oncology and Pathology, Cancer Centre Karolinska (K.P., M.H., S.S., D.G.) and Childhood Cancer Research Unit, Department of Women’s and Children’s Health (B.F.), Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden (I.H.); and Department of Pharmacology, Toxicology & Therapeutics, and the University of Kansas Cancer Center, University of Kansas Medical Center, Kansas City, Kansas (J.D.R.)
Bengt Fadeel
Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden (A.O.-W., R.C., G.P., R.C.G., B.F.); VTT Technical Research Centre of Finland, Medical Biotechnology, Turku, Finland (R.C.G.); Department of Oncology and Pathology, Cancer Centre Karolinska (K.P., M.H., S.S., D.G.) and Childhood Cancer Research Unit, Department of Women’s and Children’s Health (B.F.), Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden (I.H.); and Department of Pharmacology, Toxicology & Therapeutics, and the University of Kansas Cancer Center, University of Kansas Medical Center, Kansas City, Kansas (J.D.R.)
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
In this issue
Research ArticleArticle
Bortezomib-Induced Apoptosis Is Apaf-1 Dependent
Astrid Ottosson-Wadlund, Rebecca Ceder, Giulio Preta, Katja Pokrovskaja, Roland C. Grafström, Mats Heyman, Stefan Söderhäll, Dan Grandér, Ingrid Hedenfalk, John D. Robertson and Bengt Fadeel
Molecular Pharmacology January 1, 2013, 83 (1) 245-255; DOI: https://doi.org/10.1124/mol.112.080788
Research ArticleArticle
Bortezomib-Induced Apoptosis Is Apaf-1 Dependent
Astrid Ottosson-Wadlund, Rebecca Ceder, Giulio Preta, Katja Pokrovskaja, Roland C. Grafström, Mats Heyman, Stefan Söderhäll, Dan Grandér, Ingrid Hedenfalk, John D. Robertson and Bengt Fadeel
Molecular Pharmacology January 1, 2013, 83 (1) 245-255; DOI: https://doi.org/10.1124/mol.112.080788
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement